{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:41:53Z","timestamp":1784346113719,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014391","name":"Frankfurt University of Applied Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das Medikament Naloxon ist ein Opioidantagonist, der innerhalb von Minuten die (ateml\u00e4hmende) Wirkung von Opioiden im K\u00f6rper aufhebt. Naloxon kann dadurch zur Reduktion von Todesf\u00e4llen bei Opioid\u00fcberdosierung beitragen. \u201eTake-Home Naloxon\u201c (THN) ist eine Ma\u00dfnahme, die vom European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) und der Weltgesundheitsorganisation (WHO) empfohlen wird. Dabei werden Opioidkonsumierende und deren Angeh\u00f6rige, Freunde oder Bekannte im Umgang mit Naloxon geschult und f\u00fcr den Notfall mit dem Medikament ausgestattet.<\/jats:p><jats:p>Bisher wird THN in Deutschland \u00fcberwiegend von einzelnen Einrichtungen der Suchthilfe umgesetzt. Damit das Potenzial von THN voll genutzt werden kann, ist es notwendig, die Ma\u00dfnahme in Deutschland fl\u00e4chendeckend zu etablieren. Insbesondere in (niedrigschwelligen) Suchthilfeeinrichtungen, psychiatrischen Einrichtungen, im Rahmen von Opioidsubstitutionsbehandlungen und im Justizvollzug kann THN in das Angebot aufgenommen werden.<\/jats:p><jats:p>Dieser Diskussionsartikel greift die bisherige Entwicklung von THN in Deutschland seit 1998 auf, zeigt die Schwierigkeiten und Hindernisse einer fl\u00e4chendeckenden Umsetzung und stellt dar, wie THN als wirkungsvolle Public-Health-Ma\u00dfnahme auch in Deutschland gelingen kann. Besonders relevant ist dies angesichts der seit 10\u00a0Jahren steigenden Zahl von Drogentodesf\u00e4llen.<\/jats:p>","DOI":"10.1007\/s00103-023-03705-4","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:02:10Z","timestamp":1685098930000},"page":"1035-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Take-Home Naloxon: Ein Baustein der Drogennotfallprophylaxe auch in Deutschland","Take-home naloxone: a\u00a0building block of drug emergency prophylaxis in Germany"],"prefix":"10.1007","volume":"66","author":[{"given":"Simon","family":"Flei\u00dfner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heino","family":"St\u00f6ver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"3705_CR1","unstructured":"Die Drogenbeauftragte (2021) Zahl der an illegalen Drogen verstorbenen Menschen w\u00e4hrend der Coronapandemie um 13 Prozent gestiegen \u2013 Drogenbeauftragte. https:\/\/www.drogenbeauftragte.de\/presse\/detail\/zahl-der-an-illegalen-drogen-verstorbenen-menschen-waehrend-der-coronapandemie-um-13-prozent-gestiegen\/. Zugegriffen: 12. Okt. 2021"},{"key":"3705_CR2","unstructured":"Der Beauftragte der Bundesregierung f\u00fcr Sucht- und Drogenfragen (2022) 1.826\u00a0M\u00e4nner und Frauen in Deutschland 2021 an illegalen Drogen verstorben \u2013 Zahl erneut gestiegen \u2013 Der Beauftragte der Bundesregierung f\u00fcr Sucht- und Drogenfragen. https:\/\/www.bundesdrogenbeauftragter.de\/presse\/detail\/1826-maenner-und-frauen-in-deutschland-2021-an-illegalen-drogen-verstorben-zahl-erneut-gestiegen\/. Zugegriffen: 27. Juni 2022"},{"key":"3705_CR3","unstructured":"EMCDDA (2018) Preventing overdose deaths in Europe"},{"key":"3705_CR4","unstructured":"EMCDDA (2021) Europ\u00e4ischer Drogenbericht 2021: Trends und Entwicklungen. Publications Office, LU"},{"key":"3705_CR5","volume-title":"Prevention of acute drug-related mortality in prison populations during the immediate post-release period","author":"WHO","year":"2014","unstructured":"WHO (2014) Prevention of acute drug-related mortality in prison populations during the immediate post-release period. World Health Organization. Regional Office for Europe"},{"key":"3705_CR6","volume-title":"Community management of opioid overdose","author":"WHO","year":"2014","unstructured":"WHO (2014) Community management of opioid overdose. World Health Organization, Geneva"},{"key":"3705_CR7","unstructured":"Kraus L, Pfeiffer-Gerschel T, Kurz A (2017) Analyse drogeninduzierter Todesf\u00e4lle. IFT Institut f\u00fcr Therapieforschung, M\u00fcnchen"},{"key":"3705_CR8","volume-title":"Europ\u00e4ischer Drogenbericht. Trends und Entwicklungen","author":"EMCDDA","year":"2019","unstructured":"EMCDDA (2019) Europ\u00e4ischer Drogenbericht. Trends und Entwicklungen. Amt f\u00fcr Ver\u00f6ffentlichungen der Europ\u00e4ischen Union, Luxemburg"},{"key":"3705_CR9","unstructured":"EMCDDA (2016) Preventing opioid overdose deaths with take-home naloxone. Publications Office, LU"},{"key":"3705_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.drugalcdep.2005.01.010","volume":"79","author":"M Tracy","year":"2005","unstructured":"Tracy\u00a0M, Piper\u00a0TM, Ompad\u00a0D et\u00a0al (2005) Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend 79:181\u2013190. https:\/\/doi.org\/10.1016\/j.drugalcdep.2005.01.010","journal-title":"Drug Alcohol Depend"},{"key":"3705_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald\u00a0R, Strang\u00a0J (2016) Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 111:1177\u20131187. https:\/\/doi.org\/10.1111\/add.13326","journal-title":"Addiction"},{"key":"3705_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dar.12523","volume":"37","author":"A Olsen","year":"2018","unstructured":"Olsen\u00a0A, McDonald\u00a0D, Lenton\u00a0S, Dietze\u00a0PM (2018) Assessing causality in drug policy analyses: How useful are the Bradford Hill criteria in analysing take-home naloxone programs? Drug Alcohol Rev 37:499\u2013501. https:\/\/doi.org\/10.1111\/dar.12523","journal-title":"Drug Alcohol Rev"},{"key":"3705_CR13","volume-title":"Evaluation eines Schulungsprogramms f\u00fcr medizinische Laien zum Einsatz von nasalem Take-Home-Naloxon in Notfallsituationen bei Menschen mit Opioidabh\u00e4ngigkeit in Bayern (BayTHN)","author":"H Wodarz-von Essen","year":"2021","unstructured":"Wodarz-von Essen\u00a0H, Pogarell\u00a0O, Wolstein\u00a0J, Wodarz\u00a0N (2021) Evaluation eines Schulungsprogramms f\u00fcr medizinische Laien zum Einsatz von nasalem Take-Home-Naloxon in Notfallsituationen bei Menschen mit Opioidabh\u00e4ngigkeit in Bayern (BayTHN). Bayerisches Staatsministerium f\u00fcr Gesundheit und Pflege, M\u00fcnchen"},{"key":"3705_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/bmj.304.6835.1127","volume":"304","author":"J Strang","year":"1992","unstructured":"Strang\u00a0J, Farrell\u00a0M (1992) Harm minimisation for drug misusers. BMJ 304:1127\u20131128","journal-title":"BMJ"},{"key":"3705_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1136\/bmj.312.7044.1435","volume":"312","author":"J Strang","year":"1996","unstructured":"Strang\u00a0J, Darke\u00a0S, Hall\u00a0W et al (1996) Heroin overdose: the case for take-home naloxone. BMJ 312:1435\u20131436. https:\/\/doi.org\/10.1136\/bmj.312.7044.1435","journal-title":"BMJ"},{"key":"3705_CR16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40265-019-01154-5","volume":"79","author":"J Strang","year":"2019","unstructured":"Strang\u00a0J, McDonald\u00a0R, Campbell\u00a0G et al (2019) Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs 79:1395\u20131418. https:\/\/doi.org\/10.1007\/s40265-019-01154-5","journal-title":"Drugs"},{"key":"3705_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/bmj.322.7291.895","volume":"322","author":"K Dettmer","year":"2001","unstructured":"Dettmer\u00a0K, Saunders\u00a0B, Strang\u00a0J (2001) Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ 322:895\u2013896","journal-title":"BMJ"},{"key":"3705_CR18","unstructured":"Information Services Division (2014) National Naloxone Programme Scotland\u2014naloxone kits issued in 2013\/14 and trends in opioid-related deaths"},{"key":"3705_CR19","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill\u00a0AB (1965) The Environment and Disease: Association or Causation? Proc R Soc Med 58:295\u2013300","journal-title":"Proc R Soc Med"},{"key":"3705_CR20","first-page":"46","volume-title":"Leben retten mit Naloxon: Erfahrungen aus Deutschland, Europa und den USA","author":"K Dettmer","year":"2018","unstructured":"Dettmer\u00a0K (2018) Berlin \u2013 die Vorreiter_innen. Der Beginn der Naloxonverschreibung f\u00fcr Drogenkonsument_innen in Deutschland: ein Erfahrungsbericht. In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon: Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt am Main, S\u00a046\u201361"},{"key":"3705_CR21","first-page":"80","volume-title":"Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA","author":"G Becker","year":"2018","unstructured":"Becker\u00a0G (2018) Interview mit Gabi Becker: \u201eDie Naloxonvergabe an Laien ist f\u00fcr mich Harm Reduction pur und daher einer unserer origin\u00e4ren Arbeitsauftr\u00e4ge.\u201c. In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt a.M., S\u00a080\u201385"},{"key":"3705_CR22","first-page":"63","volume-title":"Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA","author":"M Jesse","year":"2018","unstructured":"Jesse\u00a0M (2018) K\u00f6ln: Naloxon als Empowerment in der Selbsthilfe. In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt a.M., S\u00a063\u201365"},{"key":"3705_CR23","first-page":"66","volume-title":"Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA","author":"O Ostermann","year":"2018","unstructured":"Ostermann\u00a0O (2018) Naloxon \u2013 der bayerische Weg. In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt a.M., S\u00a066\u201379"},{"key":"3705_CR24","first-page":"86","volume-title":"Leben retten mit Naloxon: Erfahrungen aus Deutschland, Europa und den USA","author":"G Schmitt","year":"2018","unstructured":"Schmitt\u00a0G (2018) Interview mit Gilbert Schmitt: Modellprojekt Take-Home-Naloxon im Saarland\/in Saarbr\u00fccken. Gen\u00fcgt Saarland? In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon: Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt am Main, S 86\u201390"},{"key":"3705_CR25","unstructured":"Vision e.\u202fV. (2018) Take-Home-Naloxon-Programme in Deutschland | VISION e.\u202fV. https:\/\/www.vision-ev.de\/2018\/10\/25\/take-home-naloxon-programme-in-deutschland\/. Zugegriffen: 3. Aug. 2022"},{"key":"3705_CR26","first-page":"34","volume-title":"Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA","author":"K Dettmer","year":"2018","unstructured":"Dettmer\u00a0K, Ostermann\u00a0O (2018) Drogennotfalltraining mit Naloxonvergabe als l\u00e4ngeres Training oder als Kurzintervention? In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt a.M., S\u00a034\u201345"},{"key":"3705_CR27","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2019","unstructured":"Ma\u00a0J, Bao\u00a0Y\u2011P, Wang\u00a0R\u2011J et al (2019) Effects of medication-assisted treatment on mortality among opioids users: a\u00a0systematic review and meta-analysis. Mol Psychiatry 24:1868\u20131883. https:\/\/doi.org\/10.1038\/s41380-018-0094-5","journal-title":"Mol Psychiatry"},{"key":"3705_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo\u00a0T Jr, Clark\u00a0B, Hickman\u00a0M et al (2021) Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. Jama Psychiatry 78:979\u2013993. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976","journal-title":"Jama Psychiatry"},{"key":"3705_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","author":"L Sordo","year":"2017","unstructured":"Sordo\u00a0L, Barrio\u00a0G, Bravo\u00a0MJ et al (2017) Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"BMJ"},{"key":"3705_CR30","doi-asserted-by":"publisher","DOI":"10.1055\/a-1860-1048","author":"HJ Wodarz-von Essen","year":"2022","unstructured":"Wodarz-von Essen\u00a0HJ, Wolstein\u00a0J, Pogarell\u00a0O, Wodarz\u00a0N (2022) Drogennotfallschulung Opioidabh\u00e4ngiger in Haft und Versorgung mit Take-Home Naloxon bei Haftentlassung: Machbarkeitsstudie aus dem bayerischen Modellprojekt. Gesundheitswesen. https:\/\/doi.org\/10.1055\/a-1860-1048","journal-title":"Gesundheitswesen"},{"key":"3705_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12954-021-00480-w","volume":"18","author":"D Jamin","year":"2021","unstructured":"Jamin\u00a0D, Vanderplasschen\u00a0W, Sys\u00a0O et\u00a0al (2021) \u201cMy first 48\u00a0hours out\u201d: drug users\u2019 perspectives on challenges and strategies upon release from prison. Harm Reduct\u00a0J 18:32. https:\/\/doi.org\/10.1186\/s12954-021-00480-w","journal-title":"Harm Reduct J"},{"key":"3705_CR32","volume-title":"Bundeseinheitliche Erhebung zur stoffgebundenen Suchtproblematik im Justizvollzug","author":"K Stoll","year":"2019","unstructured":"Stoll\u00a0K, Bayer\u00a0M, H\u00e4\u00dfler\u00a0U, Abraham\u00a0K (2019) Bundeseinheitliche Erhebung zur stoffgebundenen Suchtproblematik im Justizvollzug"},{"key":"3705_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/add.13265","volume":"111","author":"SM Bird","year":"2016","unstructured":"Bird\u00a0SM, McAuley\u00a0A, Perry\u00a0S, Hunter\u00a0C (2016) Effectiveness of Scotland\u2019s National Naloxone Programme for reducing opioid-related deaths: a\u00a0before (2006\u201310) versus after (2011\u201313) comparison. Addiction 111:883\u2013891. https:\/\/doi.org\/10.1111\/add.13265","journal-title":"Addiction"},{"key":"3705_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dar.12542","volume":"37","author":"K Horsburgh","year":"2018","unstructured":"Horsburgh\u00a0K, McAuley\u00a0A (2018) Scotland\u2019s national naloxone program: The prison experience. Drug Alcohol Rev 37:454\u2013456. https:\/\/doi.org\/10.1111\/dar.12542","journal-title":"Drug Alcohol Rev"},{"key":"3705_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1300\/J069v26n04_08","volume":"26","author":"CT Baca","year":"2007","unstructured":"Baca\u00a0CT, Grant\u00a0KJ (2007) What heroin users tell us about overdose. J\u00a0Addict Dis 26:63\u201368. https:\/\/doi.org\/10.1300\/J069v26n04_08","journal-title":"J Addict Dis"},{"key":"3705_CR36","doi-asserted-by":"publisher","first-page":"103513","DOI":"10.1016\/j.drugpo.2021.103513","volume":"100","author":"WC Tse","year":"2022","unstructured":"Tse\u00a0WC, Djordjevic\u00a0F, Borja\u00a0V et\u00a0al (2022) Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a\u00a0\u2018moral hazard\u2019 associated with naloxone supply. Int J Drug Policy 100:103513. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103513","journal-title":"Int J Drug Policy"},{"key":"3705_CR37","first-page":"123","volume-title":"Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA","author":"S Ronconi","year":"2018","unstructured":"Ronconi\u00a0S (2018) The Italien naloxone distribution model\u2014Lessons learned about an effective, sustainable and cheap harm reduction intervention. In: Dichtl\u00a0A, St\u00f6ver\u00a0H, Dettmer\u00a0K (Hrsg) Leben retten mit Naloxon. Erfahrungen aus Deutschland, Europa und den USA. Fachhochschulverlag, Frankfurt a.M., S\u00a0123\u2013142"},{"key":"3705_CR38","unstructured":"Horvath I (2017) Take home naloxone programmes in the EU and Norway. European Monitoring Centre for Drugs and Drug Addiction, Vienna"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-023-03705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-023-03705-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-023-03705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:03:13Z","timestamp":1693314193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-023-03705-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1007\/s00103-023-03705-4","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Flei\u00dfner, H.\u00a0St\u00f6ver und D.\u00a0Sch\u00e4ffer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}